• 研究課題をさがす
  • 研究者をさがす
  • KAKENの使い方
  1. 前のページに戻る

免疫寛容の高効率な誘導によるアレルギーの寛解を目指した経口性ナノ粒子製剤の開発

研究課題

研究課題/領域番号 22KJ2442
補助金の研究課題番号 22J12057 (2022)
研究種目

特別研究員奨励費

配分区分基金 (2023)
補助金 (2022)
応募区分国内
審査区分 小区分90110:生体医工学関連
研究機関九州大学

研究代表者

李 晋廷  九州大学, システム生命科学府, 特別研究員(DC2)

研究期間 (年度) 2023-03-08 – 2024-03-31
研究課題ステータス 完了 (2023年度)
配分額 *注記
1,700千円 (直接経費: 1,700千円)
2023年度: 800千円 (直接経費: 800千円)
2022年度: 900千円 (直接経費: 900千円)
キーワードallergy treatment / nanoparticle / tolerance immunity / DDS / allergy / tolerogenic nanoparticle / immunotolerance / BMDC
研究開始時の研究の概要

Currently, allergy with increasing concern. However, the treatment of allergies is not yet satisfying as side effects, time-consuming, questionable efficacy. Thus, this study is to design an immune therapy that utilizes nanoparticles to safely treat allergies. The nanoparticles will contain antigens and immunomodulators or targeted ligands to reduce the impact on normal cells while treatment. The study aims to efficiently induce immune tolerance to treat the disease. The innovation of this research lies in the screening best formulations, providing new possibilities for allergy treatment.

研究実績の概要

In the current year, my research focusing on the development of nanoparticles inducing immune tolerance for allergy treatment has made significant progress. Herein, I present an overview of my research achievements for this year:
1. Background: The number of allergy patients is on the rise. Despite immunotherapy being the only curative treatment for allergies, its high incidence of side effects and low efficacy over a treatment period of more than three years have rendered the therapy less than satisfactory. Therefore, the development of a safe and efficient treatment method has become urgent. 2. Preparation: Traditional treatment methods involve the direct administration of antigens to patients, leading to the side effects. To address this issue, I encapsulated the antigen with hydrogel nanoparticles (NP) to prevent side effects. Additionally, I modified the NP with targeting ligands to DC to enhance treatment efficiency. As results, the size of NP was adjusted to 200 nm. 3. In Vitro: NP with DC-targeting ligands significantly improved the DC uptake efficiency and increased the levels of IL-10 released by DCs, indicating their significant anti-inflammatory capabilities. 4. In Vivo: Regarding safety, NP exhibited significantly reduced binding affinity with IgE. Furthermore, repeated subcutaneous injections of NP did not induce the production of anti-drug antibodies, such as IgG and IgM. More, NP showed significant therapeutic effects on allergic model mice by decreasing IgE and the number of eosinophils.

報告書

(2件)
  • 2023 実績報告書
  • 2022 実績報告書
  • 研究成果

    (2件)

すべて 2024 2023

すべて 雑誌論文 (2件) (うち国際共著 2件、 査読あり 2件、 オープンアクセス 1件)

  • [雑誌論文] Oral Administration of PLGA Nanoparticles to Deliver Antisense Oligonucleotides to Inflammatory Lesions in the Gastrointestinal Tract2024

    • 著者名/発表者名
      Yagi Yuta、Liu Yiwei、Li Jinting、Shimada Shunsuke、Ohkouchi Munetaka、Taguchi Yasushi、Nii Teruki、Mori Takeshi、Katayama Yoshiki
    • 雑誌名

      Biological & Pharmaceutical Bulletin

      巻: 47 号: 4 ページ: 848-855

    • DOI

      10.1248/bpb.b23-00769

    • ISSN
      0918-6158, 1347-5215
    • 年月日
      2024-04-15
    • 関連する報告書
      2023 実績報告書
    • 査読あり / 国際共著
  • [雑誌論文] Safe and efficient oral allergy immunotherapy using one-pot-prepared mannan-coated allergen nanoparticles2023

    • 著者名/発表者名
      Li Shunyi、Toriumi Hiroki、Takahashi Daisuke、Kamasaki Tomoko、Fujioka Yoichiro、Nagatoishi Satoru、Li Jinting、Liu Yiwei、Hosokawa Takanatsu、Tsumoto Kouhei、Ohba Yusuke、Katayama Yoshiki、Murakami Daisuke、Hase Koji、Mori Takeshi
    • 雑誌名

      Biomaterials

      巻: 303 ページ: 122381-122381

    • DOI

      10.1016/j.biomaterials.2023.122381

    • 関連する報告書
      2023 実績報告書
    • 査読あり / オープンアクセス / 国際共著

URL: 

公開日: 2022-04-28   更新日: 2025-11-21  

サービス概要 検索マニュアル よくある質問 お知らせ 利用規程 科研費による研究の帰属

Powered by NII kakenhi